肝细胞癌免疫治疗中靶向肿瘤相关抗原：过去的困境与未来策略 - Suppr

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.

作者信息

Lu Ligong, Jiang Jun, Zhan Meixiao, Zhang Hui, Wang Qian-Ting, Sun Sheng-Nan, Guo Xiao-Kai, Yin Hua, Wei Yadong, Li Shi-You, Liu Jun O, Li Yong, He You-Wen

机构信息

Zhuhai Interventional Medical CenterZhuhai Precision Medical CenterZhuhai People's HospitalZhuhai Hospital Affiliated with Jinan UniversityZhuhaiGuangdong ProvinceP.R. China.

Tricision Biotherapeutic Inc. Jinwan DistrictZhuhaiChina.

出版信息

Hepatology. 2021 Feb;73(2):821-832. doi: 10.1002/hep.31502.

DOI:10.1002/hep.31502

PMID:32767586

Abstract

摘要

相似文献

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.

Hepatology. 2021 Feb;73(2):821-832. doi: 10.1002/hep.31502.

Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations.

World J Gastroenterol. 2020 May 7;26(17):2040-2048. doi: 10.3748/wjg.v26.i17.2040.

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.

Cancer Lett. 2020 Mar 31;473:25-32. doi: 10.1016/j.canlet.2019.12.029. Epub 2019 Dec 23.

[Immune therapy against hepatocellular carcinoma using gene-modified tumor cells].

Nihon Rinsho. 2001 Oct;59 Suppl 6:688-92.

Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.

World J Gastroenterol. 2019 Jul 7;25(25):3151-3167. doi: 10.3748/wjg.v25.i25.3151.

Immunotherapy in hepatocellular carcinoma.

Ann Hepatol. 2019 Mar-Apr;18(2):291-297. doi: 10.1016/j.aohep.2019.04.003. Epub 2019 Apr 25.

Potential of immunotherapy for hepatocellular carcinoma.

J Hepatol. 2011 Apr;54(4):830-4. doi: 10.1016/j.jhep.2010.10.013. Epub 2010 Nov 9.

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.

Hepatology. 2021 Jul;74(1):483-490. doi: 10.1002/hep.31697. Epub 2021 Jun 28.

Cancer vaccines for hepatocellular carcinoma: future directions.

Immunotherapy. 2016;8(4):391-3. doi: 10.2217/imt-2015-0018.

Immunotherapy for hepatocellular carcinoma.

Cancer Lett. 2020 Feb 1;470:8-17. doi: 10.1016/j.canlet.2019.12.002. Epub 2019 Dec 4.

引用本文的文献

The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma.

Biomark Res. 2025 Apr 12;13(1):60. doi: 10.1186/s40364-025-00774-2.

Isoxazole-based molecules restore NK cell immune surveillance in hepatocarcinogenesis by targeting TM4SF5 and SLAMF7 linkage.

Signal Transduct Target Ther. 2025 Jan 20;10(1):15. doi: 10.1038/s41392-024-02106-6.

A KIF20A-based thermosensitive hydrogel vaccine effectively potentiates immune checkpoint blockade therapy for hepatocellular carcinoma.

NPJ Vaccines. 2025 Jan 3;10(1):1. doi: 10.1038/s41541-024-01060-2.

Tumor-associated antigen-specific cell imaging based on upconversion luminescence and nucleic acid rolling circle amplification.

Mikrochim Acta. 2024 Apr 8;191(5):248. doi: 10.1007/s00604-024-06331-2.

HSP90, as a functional target antigen of a mAb 11C9, promotes stemness and tumor progression in hepatocellular carcinoma.

Stem Cell Res Ther. 2023 Sep 27;14(1):273. doi: 10.1186/s13287-023-03453-x.

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C.

J Pharm Anal. 2023 Jun;13(6):616-624. doi: 10.1016/j.jpha.2023.04.012. Epub 2023 Apr 21.

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.

Genes Dis. 2022 Mar 18;10(4):1367-1401. doi: 10.1016/j.gendis.2022.02.007. eCollection 2023 Jul.

Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma.

Turk J Gastroenterol. 2023 Jun;34(6):635-644. doi: 10.5152/tjg.2023.22134.

Novel Computed-Tomography-Based Transformer Models for the Noninvasive Prediction of PD-1 in Pre-Operative Settings.

Cancers (Basel). 2023 Jan 20;15(3):658. doi: 10.3390/cancers15030658.

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.

Front Immunol. 2022 Nov 24;13:1060497. doi: 10.3389/fimmu.2022.1060497. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.

作者信息

Lu Ligong, Jiang Jun, Zhan Meixiao, Zhang Hui, Wang Qian-Ting, Sun Sheng-Nan, Guo Xiao-Kai, Yin Hua, Wei Yadong, Li Shi-You, Liu Jun O, Li Yong, He You-Wen

机构信息

Zhuhai Interventional Medical CenterZhuhai Precision Medical CenterZhuhai People's HospitalZhuhai Hospital Affiliated with Jinan UniversityZhuhaiGuangdong ProvinceP.R. China.

Tricision Biotherapeutic Inc. Jinwan DistrictZhuhaiChina.

出版信息

Hepatology. 2021 Feb;73(2):821-832. doi: 10.1002/hep.31502.

DOI:10.1002/hep.31502

PMID:32767586

Abstract

摘要

相似文献

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.

Hepatology. 2021 Feb;73(2):821-832. doi: 10.1002/hep.31502.

Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations.

World J Gastroenterol. 2020 May 7;26(17):2040-2048. doi: 10.3748/wjg.v26.i17.2040.

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.

Cancer Lett. 2020 Mar 31;473:25-32. doi: 10.1016/j.canlet.2019.12.029. Epub 2019 Dec 23.

[Immune therapy against hepatocellular carcinoma using gene-modified tumor cells].

Nihon Rinsho. 2001 Oct;59 Suppl 6:688-92.

Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.

World J Gastroenterol. 2019 Jul 7;25(25):3151-3167. doi: 10.3748/wjg.v25.i25.3151.

Immunotherapy in hepatocellular carcinoma.

Ann Hepatol. 2019 Mar-Apr;18(2):291-297. doi: 10.1016/j.aohep.2019.04.003. Epub 2019 Apr 25.

Potential of immunotherapy for hepatocellular carcinoma.

J Hepatol. 2011 Apr;54(4):830-4. doi: 10.1016/j.jhep.2010.10.013. Epub 2010 Nov 9.

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.

Hepatology. 2021 Jul;74(1):483-490. doi: 10.1002/hep.31697. Epub 2021 Jun 28.

Cancer vaccines for hepatocellular carcinoma: future directions.

Immunotherapy. 2016;8(4):391-3. doi: 10.2217/imt-2015-0018.

Immunotherapy for hepatocellular carcinoma.

Cancer Lett. 2020 Feb 1;470:8-17. doi: 10.1016/j.canlet.2019.12.002. Epub 2019 Dec 4.

引用本文的文献

The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma.

Biomark Res. 2025 Apr 12;13(1):60. doi: 10.1186/s40364-025-00774-2.

Isoxazole-based molecules restore NK cell immune surveillance in hepatocarcinogenesis by targeting TM4SF5 and SLAMF7 linkage.

Signal Transduct Target Ther. 2025 Jan 20;10(1):15. doi: 10.1038/s41392-024-02106-6.

A KIF20A-based thermosensitive hydrogel vaccine effectively potentiates immune checkpoint blockade therapy for hepatocellular carcinoma.

NPJ Vaccines. 2025 Jan 3;10(1):1. doi: 10.1038/s41541-024-01060-2.

Tumor-associated antigen-specific cell imaging based on upconversion luminescence and nucleic acid rolling circle amplification.

Mikrochim Acta. 2024 Apr 8;191(5):248. doi: 10.1007/s00604-024-06331-2.

HSP90, as a functional target antigen of a mAb 11C9, promotes stemness and tumor progression in hepatocellular carcinoma.

Stem Cell Res Ther. 2023 Sep 27;14(1):273. doi: 10.1186/s13287-023-03453-x.

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C.

J Pharm Anal. 2023 Jun;13(6):616-624. doi: 10.1016/j.jpha.2023.04.012. Epub 2023 Apr 21.

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.

Genes Dis. 2022 Mar 18;10(4):1367-1401. doi: 10.1016/j.gendis.2022.02.007. eCollection 2023 Jul.

Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma.

Turk J Gastroenterol. 2023 Jun;34(6):635-644. doi: 10.5152/tjg.2023.22134.

Novel Computed-Tomography-Based Transformer Models for the Noninvasive Prediction of PD-1 in Pre-Operative Settings.

Cancers (Basel). 2023 Jan 20;15(3):658. doi: 10.3390/cancers15030658.

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.

Front Immunol. 2022 Nov 24;13:1060497. doi: 10.3389/fimmu.2022.1060497. eCollection 2022.

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.

作者信息

机构信息

出版信息

相似文献

引用本文的文献